Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
289 studies found for:    sirolimus cancer | Open Studies
Show Display Options
RSS Create an RSS feed from your search for:
sirolimus cancer | Open Studies
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Phase I/Ib Dose Escalation & Biomarker Study of Ceritinib (LDK378) + Everolimus for Locally Advanced or Metastatic Solid Tumors With an Expansion in Non-Small Cell Lung Cancer (NSCLC) Characterized by Abnormalities in Anaplastic Lymphoma Kinase (ALK) Expression
Conditions: Head and Neck Cancer;   Lung Cancer
Interventions: Drug: Ceritinib (LDK378);   Drug: Ceritinib (LDK378) 750 mg;   Drug: Everolimus
2 Recruiting Anakinra or Denosumab and Everolimus in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Everolimus;   Drug: Anakinra;   Drug: Denosumab
3 Not yet recruiting Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Conditions: Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer
Interventions: Other: Laboratory Biomarker Analysis;   Biological: Recombinant NY-ESO-1 Protein;   Drug: Sirolimus
4 Recruiting Everolimus, Letrozole and Trastuzumab in HR- and HER2/Neu-positive Patients
Conditions: Breast Cancer;   Solid Tumors
Interventions: Drug: Everolimus;   Drug: Trastuzumab;   Drug: Letrozole
5 Recruiting Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Conditions: Hormone-Resistant Prostate Cancer;   Metastatic Prostate Carcinoma;   Prostate Carcinoma Metastatic in the Bone;   Recurrent Prostate Carcinoma;   Stage IV Prostate Cancer
Interventions: Drug: Carboplatin;   Drug: Docetaxel;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus
6 Recruiting Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Metformin
7 Recruiting A Phase 1 Trial of Vandetanib (a Multi-kinase Inhibitor of EGFR, VEGFR and RET Inhibitor) in Combination With Everolimus (an mTOR Inhibitor) in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Vandetanib;   Drug: Everolimus
8 Recruiting Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer
Conditions: Recurrent Bladder Carcinoma;   Stage II Bladder Cancer;   Stage III Bladder Cancer;   Stage IV Bladder Cancer
Interventions: Drug: Cisplatin;   Drug: Gemcitabine Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Sirolimus;   Procedure: Therapeutic Conventional Surgery
9 Recruiting Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer
Conditions: Renal Cancer;   Chromophobe Renal Cell Carcinoma;   Birt-Hogg-Dube Syndrome
Intervention: Drug: Everolimus
10 Recruiting Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid or Cetuximab in Patients With Advanced Malignancy and Other Indications
Condition: Advanced Cancers
Interventions: Drug: Temsirolimus;   Drug: Bevacizumab;   Drug: Valproic Acid;   Drug: Cetuximab
11 Recruiting A Study Of Everolimus, Trastuzumab And Vinorelbine In HER2-Positive Breast Cancer Brain Metastases
Condition: HER-2 Positive Breast Cancer
Interventions: Drug: Everolimus;   Drug: Vinorelbine;   Drug: Trastuzumab
12 Recruiting Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors
Condition: Recurrent Childhood Brain Tumor
Interventions: Device: Tumor biology testing;   Drug: Temozolomide;   Drug: Etoposide;   Drug: Sorafenib;   Drug: Everolimus;   Drug: Erlotinib;   Drug: Dasatinib
13 Recruiting Carboplatin, Pegylated Liposomal Doxorubicin Hydrochloride, and Everolimus in Treating Patients With Relapsed Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer
Conditions: Fallopian Tube Cancer;   Peritoneal Cavity Cancer;   Recurrent Ovarian Epithelial Cancer
Interventions: Drug: everolimus;   Drug: carboplatin;   Drug: pegylated liposomal doxorubicin hydrochloride;   Other: laboratory biomarker analysis
14 Recruiting Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer
Condition: Advanced Cancers
Interventions: Drug: Hydroxychloroquine;   Drug: Sirolimus;   Drug: Vorinostat
15 Recruiting A Trial of Dasatinib (PDGFR and SRC Inhibitor), Temsirolimus and Cyclophosphamide in Patients With Advanced Solid Tumors
Condition: Solid Tumors
Interventions: Drug: Dasatinib;   Drug: Cyclophosphamide;   Drug: Temsirolimus
16 Recruiting Phase II Study of Intrauterine Device (IUD) Alone or in Combination With Everolimus in Endometrial Cancer
Condition: Endometrial Cancer
Interventions: Device: Levonorgestrel Intrauterine Device (LIUD);   Drug: Everolimus;   Behavioral: Questionnaire
17 Recruiting Women's Triple-Negative First-Line Study: Liposomal Doxorubicin, Bevacizumab and Everolimus (DAE) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy
Condition: Breast Cancer
Interventions: Drug: Everolimus;   Drug: Liposomal Doxorubicin;   Drug: Bevacizumab
18 Recruiting A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer
Condition: Advanced Solid Tumors, Non-small Cell Lung Cancer
Intervention: Drug: AMG 479, Everolimus, Panitumumab
19 Recruiting S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer
Condition: Breast Cancer
Interventions: Drug: anastrozole;   Drug: everolimus;   Drug: exemestane;   Drug: goserelin acetate;   Drug: letrozole;   Drug: leuprolide acetate;   Drug: tamoxifen citrate;   Other: placebo
20 Recruiting Analysis of Tumor Tissue and Circulating Genetic Material in the Blood to Obtain Further Insight in the Effectiveness of Everolimus When Combined With Exemestane
Conditions: Hormone Receptor Positive Malignant Neoplasm of Breast;   Metastatic Breast Cancer
Intervention: Drug: Everolimus plus Exemestane

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years